查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1377391

视神经疾病药物市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按处方类型、治疗方法、最终用户、地区和竞争细分

Optical Disorders Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Prescription Type, by Therapeutics, by End User, by region, and Competition
出版日期: | 出版商: TechSci Research | 英文 171 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年，全球视神经疾病药物市场价值为 334.5 亿美元，预计在预测期内将以 7.95% 的复合CAGR强劲增长，到 2028 年可能达到 57 亿美元。视神经疾病，也称为眼部疾病或眼科疾病是指影响眼睛和视觉系统的多种病症和疾病。这些疾病会影响眼睛各部位的结构或功能，导致视力问题、不适或其他症状。视神经疾病可影响所有年龄层的人，范围从轻微到严重。根据具体情况及其严重程度，视神经疾病的治疗方法可能会大不相同。它可能包括处方眼镜或隐形眼镜、药物（眼药水或口服药物）、手术干预、生活方式改变以及用于监测和早期发现的定期眼科检查。治疗的目标是保持和改善视力和整体眼睛健康。全球人口老化是视神经疾病药物市场的重要推手。随着个体年龄的增长，患有白内障、青光眼和黄斑部病变等与年龄相关的眼部疾病的风险增加，导致对视神经疾病药物的需求增加。

由于生活方式的改变、萤幕时间的增加以及糖尿病发病率的增加等因素，各种眼部疾病的盛行率一直在上升，包括近视、糖尿病视网膜病变和干眼症。这一趋势推动了对药物治疗的需求。眼科药物开发的进步，包括新药物配方、给药方法和诊断技术，促进了市场的成长。这些创新通常会带来更有效、对患者友善的治疗方法。医疗保健支出的整体成长，尤其是在已开发国家，支持了视神经疾病药物市场的成长。对医疗保健基础设施和服务的投资可以改善眼部护理和药物的取得。全球糖尿病病例的增加导致糖尿病视网膜病变和其他糖尿病相关眼部疾病的发生率增加。因此，对治疗这些疾病的药物的需求更高。美国食品药物管理局（FDA）和欧洲药品管理局（EMA）等监管机构对新药和创新药物的批准可以推动市场成长。这些批准为眼部疾病开闢了新的治疗选择。

主要市场驱动因素

市场概况
预测期 2024-2028
2022 年市场规模 334.5亿美元
2028 年市场规模 525.8亿美元
2023-2028 年CAGR 7.95%
成长最快的细分市场 非处方药物
最大的市场 北美洲

技术进步

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球视神经疾病药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依处方类型（非处方药、处方眼科药物）
    • 依治疗方法（老年性黄斑部病变、结膜炎、糖尿病黄斑水肿、糖尿病视网膜病变、干眼症、眼癌、青光眼等）
    • 按最终使用者（诊断中心、眼科诊所、医院）
    • 按公司划分 (2022)
  • 市场地图

第 6 章：亚太地区视神经疾病药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按处方类型
    • 透过治疗学
    • 按最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国视障药品
    • 印度视神经疾病药物
    • 澳洲视神经疾病药物
    • 日本视障药物
    • 韩国 视神经疾病药物

第 7 章：欧洲视神经疾病药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按处方类型
    • 透过治疗学
    • 按最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 8 章：北美视神经疾病药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按处方类型
    • 透过治疗学
    • 按最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 9 章：南美洲视神经疾病药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按处方类型
    • 透过治疗学
    • 按最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲视神经疾病药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按处方类型
    • 透过治疗学
    • 按最终用户
    • 按国家/地区
  • MEA：国家分析
    • 南非视神经疾病药物
    • 沙乌地阿拉伯 视神经疾病药物
    • 阿联酋视神经疾病药物

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 13 章：全球视神经疾病药物市场：SWOT 分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第 15 章：大环境分析

第16章：竞争格局

  • 爱尔康公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 诺华公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 强生服务公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 博士健康
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 默克公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 科赫鲁斯生物科学有限公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 艾尔建
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 辉瑞公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
    • SWOT Analysis
  • 拜耳公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
    • SWOT Analysis
  • 参天製药股份有限公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
    • SWOT Analysis

第 17 章：策略建议

关于我们及免责声明

简介目录
Product Code: 16840

Global Optical Disorders Drugs Market has valued at USD 33.45 billion in 2022 and is anticipated to witness a robust growth in the forecast period with a CAGR of 7.95% and will probably reach USD 5.70 billion by 2028. Optical disorders, also known as eye disorders or ophthalmic disorders, refer to a wide range of conditions and diseases that affect the eyes and visual system. These disorders can impact the structure or function of various components of the eye, leading to vision problems, discomfort, or other symptoms. Optical disorders can affect individuals of all ages and can range from mild to severe. Treatment for optical disorders can vary widely depending on the specific condition and its severity. It may include prescription eyeglasses or contact lenses, medications (eye drops or oral medications), surgical interventions, lifestyle modifications, and regular eye exams for monitoring and early detection. The goal of treatment is to preserve and improve vision and overall eye health. The global aging population is a significant driver of the optical disorder's drugs market. As individuals age, their risk of developing age-related eye conditions such as cataracts, glaucoma, and macular degeneration increases, leading to a higher demand for optical disorder drugs.

The prevalence of various eye disorders, including myopia, diabetic retinopathy, and dry eye syndrome, has been on the rise due to factors such as lifestyle changes, increased screen time, and the growing incidence of diabetes. This trend drives the demand for pharmaceutical treatments. Advancements in ophthalmic drug development, including new drug formulations, delivery methods, and diagnostic technologies, contribute to the growth of the market. These innovations often lead to more effective and patient-friendly treatments. The overall increase in healthcare spending, especially in developed countries, supports the growth of the optical disorder's drugs market. Investments in healthcare infrastructure and services lead to improved access to eye care and medications. The global rise in diabetes cases has contributed to an increased incidence of diabetic retinopathy and other diabetes-related eye conditions. As a result, there is a higher demand for drugs to manage these conditions. The approval of new and innovative drugs by regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), can drive market growth. These approvals open up new treatment options for eye disorders.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 33.45 Billion
Market Size 2028USD 52.58 Billion
CAGR 2023-20287.95%
Fastest Growing SegmentOver-The-Counter Drugs
Largest MarketNorth America

Advancements in Technology

Researchers have been working on sustained-release drug delivery systems for optical disorders. These systems allow for the controlled and gradual release of medication over an extended period, reducing the need for frequent dosing. For example, sustained-release intraocular implants can provide long-term treatment for conditions like diabetic macular edema. Nanotechnology has been applied to develop nano-sized drug delivery systems that can penetrate the eye's tissues more effectively. Nano emulsions and nanoparticles can improve the solubility and bioavailability of drugs, leading to enhanced therapeutic effects. Topical ophthalmic drug formulations, such as gels, ointments, and nano emulsions, have been developed to improve drug absorption and retention on the ocular surface. These formulations can enhance the delivery of drugs for conditions like glaucoma and dry eye syndrome. Advancements in biotechnology have led to the development of biologic drugs and gene therapies for optical disorders. These innovative treatments target specific molecular pathways involved in eye diseases, offering the potential for more precise and effective therapies. Artificial tears, used to relieve dry eye symptoms, have seen improvements in their formulations. These include preservative-free options, lipid-based tear substitutes, and products containing bioengineered molecules that mimic natural tears. Technological advancements in diagnostic tools such as optical coherence tomography (OCT) and confocal microscopy enable more accurate and early diagnosis of optical disorders. This early diagnosis allows for timely intervention and personalized treatment plans.

Contact lenses with embedded drug-delivery systems have been developed to release medications gradually into the eye. These lenses are used to manage conditions like glaucoma and corneal infections while providing vision correction. Wearable devices and smartphone apps are being used for monitoring and managing optical disorders. Patients can use these devices to track symptoms, medication schedules, and treatment progress, improving adherence to treatment regimens. Telemedicine platforms and remote monitoring technologies have become more prevalent, allowing patients to consult with eye care professionals and receive prescription medications without in-person visits. This has become particularly important during public health crises. Researchers are exploring the use of combination therapies, where multiple drugs are formulated together or administered sequentially to target different aspects of an eye condition. This approach can enhance treatment outcomes. Advances in genomics and personalized medicine enable customized treatment plans based on an individual's genetic makeup and specific disease characteristics. This tailoring of treatment can optimize outcomes and minimize side effects. In some cases, tissue engineering techniques are being used to develop artificial corneas and retinal implants to restore vision in individuals with severe optical disorders. This factor will help in the development of Global Optical Disorders Drugs Market.

Increasing Diabetes Epidemic

Diabetes can lead to various eye complications and optical disorders, and the management of these conditions often involves the use of specialized medications. Diabetic retinopathy is a common and serious eye complication associated with diabetes. It occurs when high blood sugar levels damage the blood vessels in the retina, leading to vision problems and, in severe cases, blindness. To manage diabetic retinopathy, various drugs, such as anti-VEGF (vascular endothelial growth factor) medications and corticosteroids, are used to reduce swelling and prevent abnormal blood vessel growth in the eye. Diabetic Macular Edema (DME) is a specific form of diabetic retinopathy that affects the macula, the central part of the retina responsible for sharp vision. DME can lead to vision loss. Drugs like anti-VEGF agents and corticosteroids are employed to treat DME and reduce macular edema. People with diabetes have an increased risk of developing glaucoma, an optical disorder characterized by increased intraocular pressure that can damage the optic nerve. Medications such as topical eye drops (e.g., prostaglandin analogs, beta-blockers, alpha agonists) are used to lower intraocular pressure and manage glaucoma in diabetic patients.

Individuals with diabetes are at a higher risk of developing cataracts at an earlier age. Cataracts cloud the eye's lens, leading to vision impairment. Surgical removal of cataracts is a common treatment, but medications may be prescribed to manage symptoms and prevent progression before surgery. Diabetes can lead to dry eye syndrome, a condition in which the eyes do not produce enough tears or produce poor-quality tears. Lubricating eye drops, gels, and ointments are commonly used to relieve dry eye symptoms. Diabetes can weaken the immune system and increase the risk of eye infections, such as conjunctivitis and keratitis. Antibiotics or antiviral eye drops may be prescribed to treat these infections. Regular eye examinations and retinal screenings are crucial for individuals with diabetes to detect and monitor optical disorders. The demand for these screenings, as well as the drugs used to manage detected conditions, increases with the diabetes epidemic. This factor will pace up the demand of Global Optical Disorders Drugs Market.

Rising Aging Population

Many optical disorders, such as cataracts, age-related macular degeneration (AMD), and glaucoma, become more common with advancing age. The aging population experiences a higher incidence of these conditions, necessitating the use of drugs for treatment and management. Cataracts are one of the most common age-related eye conditions. They involve the clouding of the eye's natural lens, leading to blurred vision. Cataract surgery is a common treatment, but prescription medications may be used to manage symptoms or prevent the progression of early-stage cataracts. Age-Related Macular Degeneration (AMD) is a leading cause of vision loss among older adults. Medications such as anti-VEGF drugs are used to slow the progression of AMD and preserve vision. Glaucoma risk increases with age, and it can lead to irreversible vision loss if not managed. Medications in the form of eye drops, oral medications, or even surgical options are often prescribed to lower intraocular pressure and prevent glaucoma progression. Aging is associated with changes in tear production and tear film quality, leading to dry eye syndrome. Lubricating eye drops, gels, and ointments are commonly used to relieve dry eye symptoms in older individuals.

Presbyopia is a natural age-related change in which the eye's lens loses its flexibility, making it difficult to focus on close-up objects. Medications, such as prescription eyeglasses or contact lenses, are commonly prescribed to correct presbyopia. As individuals age, changes in the retina, such as the development of drusen or retinal vein occlusion, become more common. Optical disorders drugs may be used to manage these conditions and prevent vision loss. Aging can weaken the immune system, making older adults more susceptible to eye infections and inflammation. Medications, such as antibiotics or anti-inflammatory drugs, are used to treat these conditions. Older adults are encouraged to have regular eye examinations to monitor their eye health and detect optical disorders early. This leads to increased prescriptions for medications or treatments when conditions are diagnosed. As people age, they may be more inclined to take proactive steps to maintain their eye health, including the use of preventive medications or treatments to address age-related eye conditions. This factor will accelerate the demand of Global Optical Disorders Drugs Market.

Key Market Challenges

Generic Competition

Generic competition refers to the availability of lower-cost generic versions of brand-name (innovator) drugs once their patents expire. This competition can impact both the revenues of pharmaceutical companies and the affordability of medications for patients. When generic versions of optical disorders drugs enter the market, they are typically sold at significantly lower prices than their brand-name counterparts. This price erosion can result in decreased revenue for the original drug manufacturers, as patients and healthcare providers often opt for more cost-effective options. Generic drugs can quickly gain market share, especially if they are priced competitively. This can reduce the market share and revenue of the innovator drug, even if it was previously the market leader. For pharmaceutical companies, generic competition can lead to lower profit margins on their brand-name optical disorders drugs, as they may be forced to lower prices or offer discounts to remain competitive. When a brand-name drug's patent expires, it loses exclusivity, allowing other manufacturers to produce generic versions. This can result in a loss of market dominance for the original drug. The threat of generic competition can impact the willingness of pharmaceutical companies to invest in research and development (R&D) for new optical disorders drugs. The fear of losing exclusivity and facing generic competition after patent expiration may reduce the incentive to develop innovative treatments.

Compliance and Adherence

Compliance refers to a patient's willingness to follow a healthcare provider's recommendations or treatment plan, while adherence specifically relates to a patient's ability to take medications as prescribed. In the context of optical disorders drugs, these challenges can have important implications for treatment outcomes and overall eye health. When patients do not adhere to their prescribed treatment regimens for optical disorders, they may not receive the full benefit of the medication. This can result in suboptimal treatment outcomes, including insufficient control of eye conditions or slower recovery. Non-compliance and non-adherence can lead to the progression of optical disorders. For chronic conditions like glaucoma or diabetic retinopathy, inadequate treatment can result in irreversible vision loss. Poor compliance and adherence can lead to increased healthcare costs. Patients who do not follow their prescribed treatment plans may require more frequent visits to eye care professionals, additional diagnostic tests, or even surgical interventions. Lack of understanding or awareness about the importance of adhering to treatment plans can contribute to non-compliance. Patients may not fully grasp the consequences of not taking their medications as prescribed. Some optical disorders may require complex medication regimens, including multiple eyes drops or medications with specific dosing schedules. These regimens can be challenging for patients to follow consistently. Side effects or discomfort associated with certain optical disorder drugs can deter patients from adhering to their treatment plans. They may discontinue medications prematurely to avoid side effects. Patients may face barriers to access, including the availability and affordability of medications. Anxiety, depression, or other psychological factors can affect a patient's ability or willingness to adhere to their treatment. Fear of side effects or concerns about the effectiveness of medication may play a role.

Key Market Trends

Patient Preferences

Healthcare providers are increasingly tailoring treatment plans for optical disorders based on individual patient preferences. This may include considering factors such as lifestyle, daily routines, and treatment goals when selecting medications or therapies. Patients often have preferences for the method of drug administration. For example, some individuals may prefer eye drops, while others may prefer ointments or less frequent treatments. Pharmaceutical companies are developing a variety of formulations to accommodate these preferences. Patient preferences favor medications and treatment regimens that are easy to use and fit seamlessly into their daily lives. Drug manufacturers are designing user-friendly packaging and delivery systems to enhance ease of use. Patients are more likely to adhere to treatment plans when they experience fewer side effects. Drug development efforts focus on creating medications with improved safety profiles and fewer adverse effects. Patients appreciate dosing flexibility, which allows them to adjust their medication schedule as needed. Some optical disorders drugs offer options for once daily or less frequent dosing, giving patients greater control over their treatment. Healthcare providers are placing a greater emphasis on patient education and engagement to ensure that patients understand their treatment options and feel empowered to make informed decisions based on their preferences. Shared decision-making between patients and healthcare providers is becoming more common. This collaborative approach allows patients to express their preferences and values, leading to treatment plans that align with their goals.

Segmental Insights

Prescription Type Insights

In 2022, the Global Optical Disorders Drugs Market largest share was held by Over-The-Counter Drugs segment and is predicted to continue expanding over the coming years. OTC drugs for optical disorders, such as artificial tears and eye drops for relief of dry eyes or minor irritations, offer convenience to consumers. Patients can purchase these medications without a prescription and use them as needed for symptom relief. Many optical disorders, such as dry eye syndrome, mild allergic conjunctivitis, and eye redness, are relatively common and can often be managed with OTC medications. Patients may prefer the ease of accessing these products directly from pharmacies or stores. OTC drugs are typically more affordable than prescription medications. Patients may opt for OTC options as a cost-effective solution for managing mild eye conditions before seeking prescription treatment. Consumers are often familiar with common OTC eye products due to advertising and branding. Recognizable brand names may influence consumer choices.

Therapeutics Insights

In 2022, the Global Optical Disorders Drugs Market Conjunctivitis segment is gaining significant growth and is predicted to continue expanding over the coming years. Conjunctivitis, often referred to as "pink eye," is a common eye condition characterized by inflammation of the conjunctiva, the thin membrane covering the eye's white surface. It can be caused by various factors, including infections, allergies, and irritants. The high prevalence of conjunctivitis means that there is a substantial patient population in need of treatment. Conjunctivitis can have multiple causes, including viral, bacterial, allergic, and irritant-related. This diversity in the underlying causes of the condition necessitates a range of treatment options, including prescription medications. Allergic conjunctivitis, a subtype of conjunctivitis, can be triggered by environmental allergens such as pollen and dust. With rising environmental challenges and increased allergen exposure in some regions, the incidence of allergic conjunctivitis may be on the rise.

End User Insights

In 2022, the Global Optical Disorders Drugs Market largest share was held by Eye Clinics segment in the forecast period and is predicted to continue expanding over the coming years. Eye clinics are specialized healthcare facilities that focus exclusively on eye care and vision-related issues. This specialization allows them to provide comprehensive diagnosis, treatment, and management of optical disorders. Patients with eye conditions often prefer seeking care at these clinics due to the expertise and specialized services they offer. Eye clinics often provide a patient-centred approach to care. They are dedicated to addressing the unique needs and concerns of individuals with eye disorders, which can lead to higher patient satisfaction and loyalty. Eye clinics typically employ ophthalmologists, who are medical doctors specializing in eye care. Ophthalmologists are highly trained professionals capable of diagnosing and treating a wide range of optical disorders. Their presence in eye clinics ensures that patients receive expert care. Many eye clinics have on-site pharmacies or close collaborations with pharmacies, making it convenient for patients to obtain prescription medications for optical disorders immediately after diagnosis and consultation.

Regional Insights

The North America region dominates the Global Optical Disorders Drugs Market in 2022. North America, particularly the United States and Canada, has a relatively high prevalence of eye disorders, including conditions like cataracts, glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy. The aging population in these countries contributes to the higher incidence of age-related eye conditions. North America boasts some of the most advanced and well-established healthcare infrastructures in the world. This infrastructure supports comprehensive eye care, including diagnosis, treatment, and access to a wide range of optical disorder drugs. The region's research institutions, universities, and medical centers are leaders in ophthalmic research and innovation. They play a crucial role in developing new drugs and therapies for optical disorders. Many people in North America have health insurance coverage that includes eye care and medications. This makes it easier for individuals to access prescription drugs for optical disorders, which can drive market demand.

Key Market Players

Alcon inc.

Novartis ag

Johnson & Johnson services, inc.

Bausch health

Merck & co. Inc.

Coherus biosciences, inc.

Allergan

Pfizer, inc.

Bayer ag

Santen pharmaceuticals co. Ltd.

Genetech, Inc.

Report Scope:

In this report, the Global Optical Disorders Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Optical Disorders Drugs Market, By Prescription Type:

  • Over-The-Counter Drugs
  • Prescription Ophthalmic Drugs

Optical Disorders Drugs Market, By Therapeutics:

  • Age-Related Macular Degeneration
  • Conjunctivitis
  • Diabetic Macular Edema
  • Diabetic Retinopathy
  • Dry Eye
  • Eye Cancer
  • Glaucoma
  • Others

Optical Disorders Drugs Market, By End User:

  • Diagnostic Centers
  • Eye Clinics
  • Hospitals

Global Optical Disorders Drugs Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Optical Disorders Drugs Market.

Available Customizations:

  • Global Optical Disorders Drugs Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Optical Disorders Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Prescription Type (Over-The-Counter Drugs, Prescription Ophthalmic Drugs)
    • 5.2.2. By Therapeutics (Age-Related Macular Degeneration, Conjunctivitis, Diabetic Macular Edema, Diabetic Retinopathy, Dry Eye, Eye Cancer, Glaucoma, others)
    • 5.2.3. By End User (Diagnostic Centers, Eye Clinics, Hospitals)
    • 5.2.4. By Company (2022)
  • 5.3. Market Map

6. Asia Pacific Optical Disorders Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Prescription Type
    • 6.2.2. By Therapeutics
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Optical Disorders Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Prescription Type
        • 6.3.1.2.2. By Therapeutics
        • 6.3.1.2.3. By End User
    • 6.3.2. India Optical Disorders Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Prescription Type
        • 6.3.2.2.2. By Therapeutics
        • 6.3.2.2.3. By End User
    • 6.3.3. Australia Optical Disorders Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Prescription Type
        • 6.3.3.2.2. By Therapeutics
        • 6.3.3.2.3. By End User
    • 6.3.4. Japan Optical Disorders Drugs Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Prescription Type
        • 6.3.4.2.2. By Therapeutics
        • 6.3.4.2.3. By End User
    • 6.3.5. South Korea Optical Disorders Drugs Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Prescription Type
        • 6.3.5.2.2. By Therapeutics
        • 6.3.5.2.3. By End User

7. Europe Optical Disorders Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Prescription Type
    • 7.2.2. By Therapeutics
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Optical Disorders Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Prescription Type
        • 7.3.1.2.2. By Therapeutics
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Optical Disorders Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Prescription Type
        • 7.3.2.2.2. By Therapeutics
        • 7.3.2.2.3. By End User
    • 7.3.3. Spain Optical Disorders Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Prescription Type
        • 7.3.3.2.2. By Therapeutics
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Optical Disorders Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Prescription Type
        • 7.3.4.2.2. By Therapeutics
        • 7.3.4.2.3. By End User
    • 7.3.5. United Kingdom Optical Disorders Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Prescription Type
        • 7.3.5.2.2. By Therapeutics
        • 7.3.5.2.3. By End User

8. North America Optical Disorders Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Prescription Type
    • 8.2.2. By Therapeutics
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Optical Disorders Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Prescription Type
        • 8.3.1.2.2. By Therapeutics
        • 8.3.1.2.3. By End User
    • 8.3.2. Mexico Optical Disorders Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Prescription Type
        • 8.3.2.2.2. By Therapeutics
        • 8.3.2.2.3. By End User
    • 8.3.3. Canada Optical Disorders Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Prescription Type
        • 8.3.3.2.2. By Therapeutics
        • 8.3.3.2.3. By End User

9. South America Optical Disorders Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Prescription Type
    • 9.2.2. By Therapeutics
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Optical Disorders Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Prescription Type
        • 9.3.1.2.2. By Therapeutics
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Optical Disorders Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Prescription Type
        • 9.3.2.2.2. By Therapeutics
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Optical Disorders Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Prescription Type
        • 9.3.3.2.2. By Therapeutics
        • 9.3.3.2.3. By End User

10. Middle East and Africa Optical Disorders Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Prescription Type
    • 10.2.2. By Therapeutics
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Optical Disorders Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Prescription Type
        • 10.3.1.2.2. By Therapeutics
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Optical Disorders Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Prescription Type
        • 10.3.2.2.2. By Therapeutics
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Optical Disorders Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Prescription Type
        • 10.3.3.2.2. By Therapeutics
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Optical Disorders Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. ALCON INC.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. NOVARTIS AG.
    • 16.2.1. Business Overview
    • 16.2.2. Company Snapshot
    • 16.2.3. Products & Services
    • 16.2.4. Financials (In case of listed companies)
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. JOHNSON & JOHNSON SERVICES, INC.
    • 16.3.1. Business Overview
    • 16.3.2. Company Snapshot
    • 16.3.3. Products & Services
    • 16.3.4. Financials (In case of listed companies)
    • 16.3.5. Recent Developments
    • 16.3.6. SWOT Analysis
  • 16.4. BAUSCH HEALTH
    • 16.4.1. Business Overview
    • 16.4.2. Company Snapshot
    • 16.4.3. Products & Services
    • 16.4.4. Financials (In case of listed companies)
    • 16.4.5. Recent Developments
    • 16.4.6. SWOT Analysis
  • 16.5. MERCK & CO. INC.
    • 16.5.1. Business Overview
    • 16.5.2. Company Snapshot
    • 16.5.3. Products & Services
    • 16.5.4. Financials (In case of listed companies)
    • 16.5.5. Recent Developments
    • 16.5.6. SWOT Analysis
  • 16.6. COHERUS BIOSCIENCES, INC.
    • 16.6.1. Business Overview
    • 16.6.2. Company Snapshot
    • 16.6.3. Products & Services
    • 16.6.4. Financials (In case of listed companies)
    • 16.6.5. Recent Developments
    • 16.6.6. SWOT Analysis
  • 16.7. ALLERGAN
    • 16.7.1. Business Overview
    • 16.7.2. Company Snapshot
    • 16.7.3. Products & Services
    • 16.7.4. Financials (In case of listed companies)
    • 16.7.5. Recent Developments
    • 16.7.6. SWOT Analysis
  • 16.8. PFIZER, INC.
    • 16.8.1. Business Overview
    • 16.8.2. Company Snapshot
    • 16.8.3. Products & Services
    • 16.8.4. Financials (In case of listed companies)
    • 16.8.5. Recent Developments
    • 16.8.6. SWOT Analysis
    • 16.8.7. SWOT Analysis
  • 16.9. BAYER AG
    • 16.9.1. Business Overview
    • 16.9.2. Company Snapshot
    • 16.9.3. Products & Services
    • 16.9.4. Financials (In case of listed companies)
    • 16.9.5. Recent Developments
    • 16.9.6. SWOT Analysis
    • 16.9.7. SWOT Analysis
  • 16.10. SANTEN PHARMACEUTICALS CO. LTD.
    • 16.10.1. Business Overview
    • 16.10.2. Company Snapshot
    • 16.10.3. Products & Services
    • 16.10.4. Financials (In case of listed companies)
    • 16.10.5. Recent Developments
    • 16.10.6. SWOT Analysis
    • 16.10.7. SWOT Analysis

17. Strategic Recommendations

About Us & Disclaimer